ZLSCF (ZYUS Life Sciences) Stock Based Compensation: $0.38 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLSCF ZYUS Life Sciences Corp ZLSCF
21 GF Score
Price $0.60
GF Value $0.55
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is ZYUS Life Sciences Stock Based Compensation?

ZYUS Life Sciences ZLSCF -6.89% 21 Stock Based Compensation is $0.38 Mil as of Jun. 2026. GuruFocus rates ZLSCF with a GF Score™ of 21/100 and a GF Value™ of $0.55 (Fairly Valued). The stock has 6 warning signs investors should review.

ZYUS Life Sciences's Stock Based Compensation for the three months ended in Jun. 2026 was $0.05 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was $0.38 Mil.

ZYUS Life Sciences Stock Based Compensation Related Terms

ZYUS Life Sciences Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for ZYUS Life Sciences's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZYUS Life Sciences Stock Based Compensation Chart

ZYUS Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.08 0.20 0.30 0.33

ZYUS Life Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.03 0.23 0.07 0.05
ZLSCF
21GF Score
ZYUS Life Sciences Corp ZLSCF
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ZYUS Life Sciences Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.38 Mil.

What does a Stock Based Compensation of $0.38 Mil mean?
ZYUS Life Sciences (ZLSCF) has a Stock Based Compensation of $0.38 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for ZYUS Life Sciences and its competitors.
Is ZYUS Life Sciences' Stock Based Compensation too high?
ZYUS Life Sciences' current Stock Based Compensation is $0.38 Mil. Overall, ZYUS Life Sciences has a GF Score™ of 21/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ZYUS Life Sciences' Stock Based Compensation compare to SKYI and CBDY?
ZYUS Life Sciences' Stock Based Compensation of $0.38 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for ZYUS Life Sciences and its competitors. ZYUS Life Sciences's current Stock Based Compensation is $0.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, ZYUS Life Sciences (ZLSCF) is currently considered Fairly Valued. The stock's GF Value™ is $0.55, compared to a current price of $0.60 — trading 9.1% above its estimated fair value. The current Stock Based Compensation is $0.38 Mil. ZYUS Life Sciences' overall GF Score™ is 21/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For ZYUS Life Sciences (ZLSCF), the current Stock Based Compensation is $0.38 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ZYUS Life Sciences (ZLSCF) Overvalued in 2026?

Based on GuruFocus' analysis, ZYUS Life Sciences stock appears to be overvalued. The current stock price of $0.60 is trading 9.1% above its estimated GF Value™ of $0.55. GuruFocus considers ZYUS Life Sciences to be Fairly Valued.

Key valuation signals for ZLSCF:

  • Stock Based Compensation: $0.38 Mil
  • GF Value™: $0.55 vs. price of $0.60 (9.1% above fair value)
  • GF Score™: 21/100 with 6 warning signs

No single metric tells the full story. See the ZLSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ZYUS Life Sciences Business Description

Other Exchanges ZYUS:Canada
Address 407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
21GF Score

Get the complete analysis for ZLSCF

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price
$0.55
GF Value